Efficacy and safety of rituximab in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis [0.03%]
利妥昔单抗治疗类风湿关节炎相关间质性肺病的疗效和安全性：系统评价和 Meta分析
Mahmoud Ines,Zarrouk Zeineb,Bouden Selma et al.
Mahmoud Ines et al.
Objectives: To assess the effectiveness and safety of Rituximab (RTX) treatment among patients diagnosed with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). ...
Correction [0.03%]
改正措施
Published Erratum
Expert opinion on biological therapy. 2025 Sep 10:1. DOI:10.1080/14712598.2025.2559467 2025
Neoadjuvant therapy of NSCLC: a review of the use and impact of monoclonal antibodies [0.03%]
非小细胞肺癌术前治疗的单克隆抗体使用及影响分析
Danilo Rocco,Luigi Della Gravara,Cristina Boccia et al.
Danilo Rocco et al.
Introduction: From the 1960s and up until 2021, neoadjuvant chemotherapy has represented the standard of care for potentially resectable stage III (N2) Non-Small Cell Lung Cancer (NSCLC). However, in recent years, immunot...
Combining VEGF and PD-1/PD-L1 inhibition in advanced hepatocellular carcinoma: clinical trials, real-world evidence, and future directions [0.03%]
联合应用VEGF和PD-1/PD-L1抑制剂治疗晚期肝细胞癌：临床试验、真实世界证据及未来方向
Rita Balsano,Martina Pino,Elisa Bocchero et al.
Rita Balsano et al.
Introduction: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide with most of patients diagnosed at advanced stage. Thus, systemic therapy remains a cornerstone of treatment. In ...
Efficacy and safety of biosimilars in gastroenterology: a focus on inflammatory bowel disease management [0.03%]
胃肠病学中的生物类似药的有效性和安全性：关注炎症性肠病的管理
Fruzsina Balogh,Dorottya Angyal,Adam Varga et al.
Fruzsina Balogh et al.
Introduction: The introduction of biosimilars changed the management of biologicals in inflammatory bowel disease (IBD) since the approval of CT-P13, the first biosimilar to infliximab, by the European Medicines Agency (E...
Personalized therapy in metastatic colorectal cancer: biomarker-driven use of biologics [0.03%]
转移性结直肠癌的个体化治疗：生物标志物指导下的生物制剂使用
Francesco Sullo,Chiara Gallio,Laura Matteucci et al.
Francesco Sullo et al.
Introduction: Metastatic colorectal cancer (mCRC) remains a leading cause of cancer mortality worldwide, with limited long-term survival despite therapeutic advances. The increasing understanding of its molecular heteroge...
An evaluation of zanidatamab, a novel, anti-HER2 biparatopic antibody, for the treatment of biliary tract cancer [0.03%]
评估新型抗HER2双结合域抗体zanidatamab治疗胆道癌的效果
Jeesun Yoon,Do-Youn Oh
Jeesun Yoon
Introduction: Zanidatamab is a humanized biparatopic IgG antibody that selectively inhibits HER2 signaling pathway by targeting two distinct epitopes in the extracellular domains II and IV of HER2. Zanidatamab received ac...
Long-term effectiveness and safety of ustekinumab in patients with Crohn' s disease: real-world evidence [0.03%]
乌司奴单抗维持克罗恩病患者长期有效和安全的现实证据
Yumei Wu,Linlin Zhou,Mengqi Huang et al.
Yumei Wu et al.
Background: Ustekinumab (UST) is an interleukin-12/interleukin-23 receptor antagonist approved for the treatment of Crohn's disease (CD). Although UST has demonstrated good efficacy and safety in CD, long-term real-world ...
Miguel Sogbe,Paloma Sangro,Manuel de la Torre-Aláez et al.
Miguel Sogbe et al.
Introduction: Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality globally. For years, systemic treatment options were limited to tyrosine kinase inhibitors with modest outcomes. The introduction of...
Perceived benefits and cost savings of liquid formulation of intravenous infliximab: perspectives of seven European countries [0.03%]
欧洲七国关于注射用英夫利西单抗液体制剂的感知效益和成本节约观点
Kyoungwan Nam,Taek Sang Kwon,Federico Di Biasio et al.
Kyoungwan Nam et al.
Background: Following the approval of intravenous (IV) infliximab (IFX) in the 1990s, Celltrion developed the first monoclonal antibody biosimilar for IV IFX (Remsima®: Celltrion, South Korea), followed by the first and ...